Comparative effect of daily teriparatide, weekly teriparatide, or bisphosphonate on bone microarchitecture in patients with primary osteoporosis: A HR-pQCT study
- Conditions
- Primary osteoporosis
- Registration Number
- JPRN-UMIN000020584
- Lead Sponsor
- agasaki University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 130
Not provided
1)Patients with serious cardiac disorder, serious liver dysfunction, serious kidney dysfunction, diabetes mellitus, endocrine and metabolic diseases which may affect to the bone metabolism, and secondary osteoporosis (e.g., glucocorticoid-induced osteoporosis, rheumatoid arthritis, immobilization osteoporosis) 2)Patients treated with medication which affect to the bone metabolism as follows, i)Glucocorticosteroids (within 6 months before enrollment, or >5mg for over 3 months) except inhaler or nasal drip ii)Anti-cancer drugs iii)Anti-osteoporosis drugs (teriparatide, anti-RANKL antibody, bisphosphonates within 6 months before enrollment, SERMs within 3 months before enrollment, or estrogen preparations) 3)Patients who have contraindication of teriparatide or bisphosphonate 4)Patients who have severe allergy 5)Patients enrolled in other clinical studies in the past 3 months. 6)Patients judged to be inadequate for this study by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of cortical thickness changes after 18 months
- Secondary Outcome Measures
Name Time Method The change of bone mineral density, bone microarchitecture, geometry and strength after 18 and 24 months